Delivery Order SPE2DB22D3016-SPE2DB24FBAZ9
Award Date
7/15/24
Potential Completion Date
8/5/24
Potential Value
$46K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 mg/10 mL vials. The delivery order, valued at $23,118.08, has an ultimate completion date of April 22, 2024. This award is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a period of performance through...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4564133145 OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. The contract has a ceiling value of $46,236.16 and runs through April 22, 2024. This delivery order falls under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp with a potential value of up to $999,999,999.00 and a...
The Defense Logistics Agency (DLA) awarded a $34,677.12 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA to provide a comprehensive range of pharmaceutical products and medical supplies to military treatment...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to the Corporate Office division of Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide OCREVUS 300 MG/10 ML VIAL 10ML. The $23,118.08 contract has a June 3, 2024 ultimate completion date. This award is made under Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The award has a ceiling value of $115,590.40 and a period of performance through April 10, 2024. This order is placed against an indefinite delivery contract (IDC) previously awarded to AmerisourceBergen Drug Corp by DLA, with a potential...
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the supply of 4564617533 ! OCREVUS 300 MG/10 ML VIAL 10ML. The delivery order, valued at $23,118.08, is a firm fixed price contract with a completion date of June 6, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999.00 and...
The U.S. Defense Logistics Agency Troop Support Medical has awarded a $115,590.40 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the...
This is a $48,077.16 firm-fixed-price delivery order contract awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract has an ultimate completion date of July 2, 2025 and is not set aside for any particular business category. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corporation's Corporate Office division to provide Ocrevus 300 mg/10 ml vials. The fixed-price contract, valued at $69,354.24, has a completion date of June 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle for...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $34,955.36 and is a Firm Fixed Price Delivery Order that runs through April 2025. The contract does not have a set-aside designation, indicating it was open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...